Irvine-based Pegasus Biologics has raised $20M in a Series C round, the company said Thursday. The round was led by ONSET Ventures, and also included prior investors Three Arch Partners, Frazier Healthcare Ventures, and new investor Affinity Capital Management. Pegasus Biologics is developing bioimplants for soft tissue repair and for care of wounds due to diabetic ulcers. The firm said the funding brings it total investment to just under $32M. More information »